Page 50 - Read Online

Page 16 of 17 Nasr et al. Metab Target Organ Damage 2023;3:19 https://dx.doi.org/10.20517/mtod.2023.20

ultrasound-guided minimally invasive autopsy. Histopathology 2020;77:186-97. DOI PubMed PMC
138. Elsoukkary SS, Mostyka M, Dillard A, et al. Autopsy findings in 32 patients with COVID-19: a single-institution experience.
Pathobiology 2021;88:56-68. DOI PubMed PMC
139. Falasca L, Nardacci R, Colombo D, et al. Postmortem findings in italian patients with COVID-19: a descriptive full autopsy study of
cases with and without comorbidities. J Infect Dis 2020;222:1807-15. DOI PubMed PMC
140. Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at
autopsy in COVID-19: a case series. EClinicalMedicine 2020;24:100434. DOI PubMed PMC
141. Lagana SM, Kudose S, Iuga AC, et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical,
histologic, and virologic data. Modern Pathology 2020;33:2147-55. DOI PubMed PMC
142. Sonzogni A, Previtali G, Seghezzi M, et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular
alterations. Liver Int 2020;40:2110-6. DOI PubMed PMC
143. Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core
biopsies. Mod Pathol 2020;33:1007-14. DOI PubMed PMC
144. Trevenzoli M, Guarnaccia A, Alberici I, et al. SARS-CoV-2 and hepatitis. J Gastrointestin Liver Dis 2020;29:473-5. DOI
145. Zhao CL, Rapkiewicz A, Maghsoodi-Deerwester M, et al. Pathological findings in the postmortem liver of patients with coronavirus
disease 2019 (COVID-19). Hum Pathol 2021;109:59-68. DOI PubMed PMC
146. Greuel S, Ihlow J, Dragomir MP, et al. COVID-19: autopsy findings in six patients between 26 and 46 years of age. Int J Infect Dis
2021;108:274-81. DOI PubMed PMC
147. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir
Med 2020;8:420-2. DOI PubMed PMC
148. Cai Q, Huang D, Yu H, et al. COVID-19: abnormal liver function tests. J Hepatol 2020;73:566-74. DOI PubMed PMC
149. McConnell MJ, Kawaguchi N, Kondo R, et al. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. J
Hepatol 2021;75:647-58. DOI PubMed PMC
150. Yurdaisik I, Demiroz AS, Oz AB, et al. Postmortem biopsies of the lung, heart, liver, and spleen of COVID-19 patients. Cureus
2021;13:e20734. DOI PubMed PMC
151. Ramos-Rincon JM, Alenda C, García-Sevila R, et al. Histopathological and virological features of lung, heart and liver percutaneous
tissue core biopsy in patients with COVID-19: a clinicopathological case series. Malays J Pathol 2022;44:83-92. PubMed
152. Chornenkyy Y, Mejia-Bautista M, Brucal M, et al. Liver pathology and SARS-CoV-2 detection in formalin-fixed tissue of patients
with COVID-19. Am J Clin Pathol 2021;155:802-14. DOI PubMed PMC
153. Fraga M, Moradpour D, Artru F, et al. Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis. J
Hepatol 2020;73:967-70. DOI PubMed PMC
154. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using openSAFELY. Nature
2020;584:430-6. DOI PubMed PMC
155. Wahlang B, Jin J, Beier JI, et al. Mechanisms of environmental contributions to fatty liver disease. Curr Environ Health Rep
2019;6:80-94. DOI PubMed PMC
156. Wahlang B, Beier JI, Clair HB, et al. Toxicant-associated steatohepatitis. Toxicol Pathol 2013;41:343-60. DOI PubMed PMC
157. Foulds CE, Treviño LS, York B, Walker CL. Endocrine-disrupting chemicals and fatty liver disease. Nat Rev Endocrinol
2017;13:445-57. DOI PubMed PMC
158. Shi H, Jan J, Hardesty JE, et al. Polychlorinated biphenyl exposures differentially regulate hepatic metabolism and pancreatic
function: Implications for nonalcoholic steatohepatitis and diabetes. Toxicol Appl Pharmacol 2019;363:22-33. DOI PubMed PMC
159. Lonardo A, Mantovani A, Lugari S, Targher G. NAFLD in some common endocrine diseases: prevalence, pathophysiology, and
principles of diagnosis and management. Int J Mol Sci 2019;20:2841. DOI PubMed PMC
160. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology 2020;158:1851-64. DOI
PubMed
161. Ferrandino G, Kaspari RR, Spadaro O, et al. Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic
mechanisms. Proc Natl Acad Sci U S A 2017;114:E9172-80. DOI PubMed PMC
162. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary
dysfunction. Hepatology 2004;39:909-14. DOI PubMed
163. Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol 2003;37:340-3.
DOI PubMed
164. Chung GE, Kim D, Kim W, et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol 2012;57:150-6.
DOI
165. Xu L, Ma H, Miao M, Li Y. Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: a
prospective case-control study. J Hepatol 2012;57:1153-4. DOI PubMed
166. Lonardo A, Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Targher G. Pathogenesis of hypothyroidism-induced NAFLD:
evidence for a distinct disease entity? Dig Liver Dis 2019;51:462-70. DOI PubMed
167. Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre,
randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2019;394:2012-24. DOI
168. Cerda C, Pérez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol